Breast augmentation with implants is a popular cosmetic surgery that enhances breast volume and contour through various placement planes.In this review,we examine the impact of subglandular,subpectoral,and subfascial ...Breast augmentation with implants is a popular cosmetic surgery that enhances breast volume and contour through various placement planes.In this review,we examine the impact of subglandular,subpectoral,and subfascial implant planes on postoperative outcomes and complication rates.Subglandular placement offers simplicity but is associated with higher risks of capsular contracture,hematoma,and rippling in patients with low tissue coverage.The subpectoral plane,widely adopted for its natural appearance and reduced capsular contracture risk,may cause dynamic deformity due to muscle contraction.Although technically challenging,the subfascial plane combines the benefits of soft tissue support and reduced implant displacement.We highlight the importance of choosing an optimal implant plane tailored to each patient’s anatomical and aesthetic needs to enhance surgical outcomes and minimize complications.Further research is needed to validate long-term efficacy,particularly for subfascial placement.展开更多
Introduction,Breast cancer is the most common cancer type in adolescents and young adults<40 years of age,accounting for 30%of cancers in this age group1.Breast cancer in the young presents significant challenges f...Introduction,Breast cancer is the most common cancer type in adolescents and young adults<40 years of age,accounting for 30%of cancers in this age group1.Breast cancer in the young presents significant challenges for patients and society,including more aggressive tumor biology,poor prognosis,genetic susceptibility,fertility preservation,and complex psychosocial issues.Moreover,because of the markedly younger median age of breast cancer,the proportion of young breast cancer patients in China is significantly higher than Western countries2.The first Young Breast Cancer in China(YBCC)consensus meeting was held in Guangzhou,China in December 2021 to address exclusive challenges and requirements facing young patients with breast cancer.Chinese medical experts from multiple specialties had an extensive discussion and formulated a consensus over several hot topics in young patients with breast cancer.The“Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer in China(2022 edition)”published in the Chinese Medical Journal has garnered significant attention3,highlighting enormous interest in the YBCC consensus in the medical community and public.展开更多
Background:Sclerosing adenosis(SA)and breast cancer(BC)often exhibit overlapping clinical,imaging,and pathological characteristics,making them difficult to differentiate.SA may also coexist with BC(SA+BC),including du...Background:Sclerosing adenosis(SA)and breast cancer(BC)often exhibit overlapping clinical,imaging,and pathological characteristics,making them difficult to differentiate.SA may also coexist with BC(SA+BC),including ductal carcinoma in situ(SA-DCIS)and invasive breast cancer(SA-IBC),which complicates diagnosis even when core-needle biopsy(CNB)suggests SA.This study aimed to develop interpretable AI-based binary and ternary classification models that leverage clinical and imaging features to distinguish SA-only from SA+BC and to further differentiate among SA-only,SA-DCIS,and SA-IBC.Methods:We retrospectively analyzed a cohort of 726 patients with SA(January 2006 to December 2021),comprising 537 SA-only and 189 SA+BC cases(90 SA-DCIS,99 SA-IBC).Multiple machine learning algorithms-logistic regression,support vector machine,decision tree,XGBoost,and random forest-were compared using AUC,accuracy,F1-score,and C-index.Model interpretability was assessed with SHAP to elucidate feature contributions and identify key predictors.Additionally,we incorporated an independent external validation cohort consisting of 113 patients to verify the model's effectiveness.展开更多
Breast cancer(BC)remains the most frequently diagnosed malignancy worldwide,with an estimated 2.3 million new cases and approximately 685,000 deaths reported in 2020.Forecasts suggest a substantial rise in global inci...Breast cancer(BC)remains the most frequently diagnosed malignancy worldwide,with an estimated 2.3 million new cases and approximately 685,000 deaths reported in 2020.Forecasts suggest a substantial rise in global incidence,with new annual cases projected to reach 3.2 million by 2050,representing a 39%increase.Additionally,BC is expected to account for approximately 7.7%of the anticipated$25.2 trillion global economic burden associated with cancer by 2050.These trends underscore an urgent need for affordable,widely accessible and effective therapeutic strategies,particularly in low-and middle-income countries.Statins,commonly prescribed for the treatment of hypercholesterolaemia via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA)reductase,have garnered increasing interest for their potential anticancer properties.This review focuses on the mechanistic underpinnings and therapeutic implications of statin use,particularly simvastatin,in the context of BC.Statins exert their primary effect through inhibition of the mevalonate pathway,which is crucial for cholesterol and isoprenoid biosynthesis.Disruption of this pathway impairs the prenylation of key signalling proteins,including members of the Ras and Rho GTPase families,which are essential for cancer cell proliferation,survival and metastasis.Preclinical evidence has demonstrated that simvastatin can induce tumour cell apoptosis,arrest cell-cycle progression and inhibit oncogenic signalling pathways.These effects have been particularly pronounced in hormone receptor-negative and triple-negative breast cancer(TNBC)subtypes,which are often associated with poor prognosis and limited treatment options.Epidemiological and observational studies further support a potential association between statin use and reduced BC recurrence and mortality.Nevertheless,robust evidence from randomised controlled trials remains limited,and further investigation is required to establish causality and define optimal therapeutic regimens.Given their well-established safety profile,global accessibility and pleiotropic effects,statins,especially simvastatin,represent a promising class of repurposed drugs in the adjuvant treatment of BC.This review synthesises evidence from the past two decades,highlighting the need for continued clinical research to validate and optimise the use of statins as adjunctive agents in BC therapy.展开更多
Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of ...Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of international guidelines,regional adaptations,and the rapidly evolving fields of precision medicine and artificial intelligence(AI).展开更多
Breast cancer is the most common malignant tumor among women globally and poses a major public health challenge due to limitations in traditional diagnostic and treatment processes,such as subjective interpretation bi...Breast cancer is the most common malignant tumor among women globally and poses a major public health challenge due to limitations in traditional diagnostic and treatment processes,such as subjective interpretation biases and inefficient multidimensional data integration.Artificial intelligence(AI),particularly deep learning and machine learning technologies,has emerged as a transformative tool in addressing these issues.Clinically,AI has been widely applied in imaging screening to improve detection rates and reduce reading time,digital pathology for precise tumor typing and gene mutation prediction,treatment decisionsupport systems to enhance guideline compliance,and drug research and development to accelerate target identification and virtual screening.Despite these achievements,AI implementation faces challenges,such as data standardization issues,limited model generalization,low clinical accessibility,and unclear ethical-legal responsibilities,which require targeted solutions that include national data standards,multi-center training,hierarchical physician training,and explainable AI.Future directions involve multimodal data integration,human-AI collaborative multidisciplinary team models,and extension to full-cycle health management from prevention-to-rehabilitation.This review provides a systematic overview of the role of AI in breast cancer care,offering insights for clinical practice and scientific research innovation,and supporting the transition toward personalized and intelligent medicine in oncology.展开更多
Objectives:Progesterone(P4)is believed to inhibit breast cancer growth,but its role in counteracting estrogen(E2)-driven progression remains unclear.This study aimed to investigate the inhibitory effect of P4 on E2-in...Objectives:Progesterone(P4)is believed to inhibit breast cancer growth,but its role in counteracting estrogen(E2)-driven progression remains unclear.This study aimed to investigate the inhibitory effect of P4 on E2-induced cell proliferation,migration,and invasion in Estrogen receptor(ER)+/progesterone receptor(PR)+breast cancer cells by examining its regulatory role in the epithelial-mesenchymal transition(EMT).Methods:ER and PRpositive MCF-7 clonal variant(MCF-7 CV)breast cancer cells were treated with E2 and co-treated with various concentrations of P4.The effects on cell proliferation,migration,and invasion were assessed.The expression of key EMT markers(E-cadherin,N-cadherin,vimentin),transcription factors(Snail,Slug),and apoptosis-related genes(p53,B-cell lymphoma 2[BCL-2],BCL2-associated X[BAX])were analyzed.Results:P4 significantly inhibited E2-induced cell proliferation in a dose-dependent manner.In the presence of E2,P4 treatment reversed EMT characteristics by increasing E-cadherin while decreasing N-cadherin,vimentin,Snail,and Slug.Consequently,P4 inhibited E2-stimulated cell migration and invasion.Furthermore,P4 treatment promoted apoptosis by upregulating BAX and p53 and downregulating BCL-2.Conclusion:Progesterone can counteract estrogen-driven breast cancer progression in ER+/PR+cells by inhibiting proliferation,reversing the EMT process,and inducing apoptosis.These findings provide mechanistic insight into the protective role of PR signaling in breast cancer.展开更多
Sign language is a primary mode of communication for individuals with hearing impairments,conveying meaning through hand shapes and hand movements.Contrary to spoken or written languages,sign language relies on the re...Sign language is a primary mode of communication for individuals with hearing impairments,conveying meaning through hand shapes and hand movements.Contrary to spoken or written languages,sign language relies on the recognition and interpretation of hand gestures captured in video data.However,sign language datasets remain relatively limited compared to those of other languages,which hinders the training and performance of deep learning models.Additionally,the distinct word order of sign language,unlike that of spoken language,requires context-aware and natural sentence generation.To address these challenges,this study applies data augmentation techniques to build a Korean Sign Language dataset and train recognition models.Recognized words are then reconstructed into complete sentences.The sign recognition process uses OpenCV and MediaPipe to extract hand landmarks from sign language videos and analyzes hand position,orientation,and motion.The extracted features are converted into time-series data and fed into a Long Short-Term Memory(LSTM)model.The proposed recognition framework achieved an accuracy of up to 81.25%,while the sentence generation achieved an accuracy of up to 95%.The proposed approach is expected to be applicable not only to Korean Sign Language but also to other low-resource sign languages for recognition and translation tasks.展开更多
Breast cancer is one of the most prevalent malignancies among women and comprises a heterogeneous spectrum of molecular subtypes with distinct biological behaviors.Among various regulatory molecules,sphingolipids play...Breast cancer is one of the most prevalent malignancies among women and comprises a heterogeneous spectrum of molecular subtypes with distinct biological behaviors.Among various regulatory molecules,sphingolipids play pivotal roles in dynamically modulating fundamental cellular processes such as proliferation,apoptosis,and metastasis through metabolic interconversions,including phosphorylation,glycosylation,and the generation of sphingosine-1-phosphate.This review aims to elucidate the mechanisms through which sphingolipid metabolism orchestrates cancer cell fate and drives breast cancer progression.Particular emphasis is placed on the balance between proapoptotic ceramides and pro-survival metabolites,such as sphingosine-1-phosphate,which collectively influence tumor growth and the therapeutic response.Additional sphingolipid species,including glucosylceramide and gangliosides(GD2,GD3,GM1,and GM3),have also been implicated in promoting breast cancer development.Furthermore,sphingolipid-based therapeutic strategies,including immunotherapy and antibody therapy,are discussed.By providing a comprehensive overview of sphingolipid metabolism,this review aims to identify novel therapeutic targets that may help overcome treatment resistance and improve clinical outcomes in breast cancer.展开更多
The landscape of breast cancer treatment has undergone a transformative shift with the integration of immunotherapy.Historically considered a“cold”tumor with limited immunogenicity,breast cancer management was domin...The landscape of breast cancer treatment has undergone a transformative shift with the integration of immunotherapy.Historically considered a“cold”tumor with limited immunogenicity,breast cancer management was dominated by surgery,chemotherapy,radiotherapy,and targeted therapies1.However,the advent of immune checkpoint inhibitors(ICIs)has challenged this paradigm,opening a new frontier.The initial breakthrough in triple-negative breast cancer(TNBC)demonstrated that a subset of patients could derive profound and durable clinical benefit from pembrolizumab and atezolizumab2,3.Today,precision immunotherapy aims to identify the patients most likely to respond,to convert immunologically silent tumors into responsive tumors,and to strategically combine immunotherapies with other modalities to overcome resistance.This evolution from empirical application to biomarker-driven strategies marks the critical juncture at which we stand,transitioning promising clinical trial data into refined,effective,and accessible clinical practice4.Recent key clinical studies on breast cancer immunotherapy are summarized in Table 1.展开更多
Legal case classification involves the categorization of legal documents into predefined categories,which facilitates legal information retrieval and case management.However,real-world legal datasets often suffer from...Legal case classification involves the categorization of legal documents into predefined categories,which facilitates legal information retrieval and case management.However,real-world legal datasets often suffer from class imbalances due to the uneven distribution of case types across legal domains.This leads to biased model performance,in the form of high accuracy for overrepresented categories and underperformance for minority classes.To address this issue,in this study,we propose a data augmentation method that masks unimportant terms within a document selectively while preserving key terms fromthe perspective of the legal domain.This approach enhances data diversity and improves the generalization capability of conventional models.Our experiments demonstrate consistent improvements achieved by the proposed augmentation strategy in terms of accuracy and F1 score across all models,validating the effectiveness of the proposed method in legal case classification.展开更多
Background:As a heterogeneous disease,breast cancer requires refined classification frameworks that can effectively guide targeted therapies.However,traditional methods fail to capture the comprehensive molecular insi...Background:As a heterogeneous disease,breast cancer requires refined classification frameworks that can effectively guide targeted therapies.However,traditional methods fail to capture the comprehensive molecular insights needed for this purpose.Methods:To comprehensively capture breast cancer heterogeneity,we employed integrative clustering that incorporates six molecular features from 670 breast cancer samples.Ten distinct clustering algorithms were combined to ensure robust subtype identification,and the identified subtypes were validated in four independent datasets.Subsequently,we constructed a survival support vector machine prognostic model based on key molecular features to enhance survival prediction and clinical applicability.Results:Five novel subtypes were identified:consensus subtypes 1–5(CS1–CS5).CS2 was an aggressive subtype with elevated TP53 mutation rates,high tumor mutational burden,and strong sensitivity to YM-155 and ispinesib.Conversely,CS5 exhibited stable genomics with enhanced nucleotide excision repair and favorable prognoses.CS2 and CS4 showed enriched immune checkpoint expression,indicating potential immunotherapy responsiveness,while CS1 and CS5 exhibited immune-cold profiles.The survival support vector machine model effectively predicted survival outcomes across independent datasets.Conclusions:The refined breast cancer classification framework developed in this research uncovers new insights into molecular heterogeneity,enhances risk stratification,and enables the identification of promising therapeutic targets.The potential of this framework to optimize personalized treatment strategies warrants further clinical validation.展开更多
Objectives:Breast cancer(BC)is the leading cause of cancer-related mortality in women,largely due to metastasis.This study aims to explore the role of purine nucleoside phosphorylase(PNP),a key enzyme in purine metabo...Objectives:Breast cancer(BC)is the leading cause of cancer-related mortality in women,largely due to metastasis.This study aims to explore the role of purine nucleoside phosphorylase(PNP),a key enzyme in purine metabolism,in the aggressiveness and metastatic behavior of BC.Methods:A comprehensive analysis was performed using in silico transcriptomic data(n=2509 patients),immunohistochemical profiling of BC tissues(n=103),and validation through western blotting in multiple BC cell lines.Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource(TIMER),Gene Expression Profiling Interactive Analysis 2(GEPIA2),and the cBioPortal for cancer genomics(cBioPortal)platforms.Correlations between PNP and key epithelial–mesenchymal transition(EMT)markers,molecular subtypes,tumor grades,and stages were examined.Results:PNP was significantly overexpressed in human epidermal growth factor receptor 2(HER-2)-positive and triple-negative BCs compared to luminal subtypes.High PNP levels were strongly associated with advanced BC stages,high-grade tumors,EMT phenotypes,and poor overall survival.Notably,HER-2 inhibition suppressed PNP expression,while PNP gene silencing induced HER-2 upregulation,revealing a reciprocal regulatory loop.Dual inhibition of PNP and HER-2 resulted in a significant reduction in cell viability compared to HER-2 inhibition alone.Conclusion:Collectively,PNP emerges as a promising biomarker of BC aggressiveness and progression.Its reciprocal interaction with HER-2 underscores its potential as a therapeutic target.Dual targeting of PNP and HER-2 may offer a novel strategy for improving outcomes in aggressive BC subtypes.展开更多
Neoadjuvant therapy(NAT)has become the standard treatment for patients with locally advanced breast cancer and stage II-III HER2-positive(HER2+)or triple-negative breast cancer(TNBC)1,2.It is essential to accurately m...Neoadjuvant therapy(NAT)has become the standard treatment for patients with locally advanced breast cancer and stage II-III HER2-positive(HER2+)or triple-negative breast cancer(TNBC)1,2.It is essential to accurately mark the primary breast tumor and positive axillary lymph nodes(ALNs)prior to NAT to ensure precise surgical excision,guide axillary downstaging,and guarantee reliable lesion retrieval for pathologic evaluation3.The false-negative rate of sentinel lymph node biopsy(SLNB)after NAT can be reduced to<10%by applying modalities,such as the identification of≥3 sentinel lymph nodes(SLNs)with dual-mapping techniques or removal of the marked lymph node with target axillary dissection(TAD)according to the ASCO,NCCN,and CBCS guidelines3-5.However,there is a lack of consensus regarding the optimal methods and materials for accurate marking6,7.Conventional techniques include clip placement,guidewire localization,and carbon or ink tattooing,whereas wireless technologies,such as MagseedR,radiofrequency identification tags,SAVI SCOUTR,and radioactive iodine-125(125I)seeds,have also been adopted.Traditional marking techniques have a localization failure rate of approximately 10%.In contrast,the use of 125I seeds(with a radiation dose of 0.1-0.3 mCi)has significantly improved localization accuracy8,9.Nevertheless,owing to radioactive properties,concerns have been raised regarding the potential impact of 125I seed marking on assessing the pathologic complete response(pCR)after NAT10.Moreover,whether the influence of 125I seed marking on pCR could lead to suboptimal adjuvant treatment decisions and potentially compromise long-term oncologic outcomes has not been established.To investigate the potential impact of 125I seed placement on the pCR rate and long-term outcomes in breast cancer patients receiving NAT,we conducted a retrospective cohort study utilizing propensity score matching(PSM).展开更多
Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strateg...Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strategies imperative.Although elevated expression of discs large homolog 3(DLG3)has been reported in BRCA,its functional role in disease progression remains unclear.We performed bioinformatic analyses of clinical datasets to evaluate the prognostic significance of DLG3 expression in BRCA patients.In vitro gain-and loss-of-function experiments were conducted to assess the impact of DLG3 on BRCA cell proliferation,migration,and colony formation.Transcriptomic profiling,coupled with pharmacological inhibition,was employed to identify and validate downstream signaling pathways.Additionally,we extended our validation to an in vivo model to assess the role of DLG3 in tumor progression.We found that elevated DLG3 levels correlated with poor prognosis in breast cancer patients.Functionally,DLG3 overexpression significantly promoted cell proliferation and migration in estrogen receptor-positive MCF7 and triple-negative MDA-MB-231 breast cancer cells,whereas its knockdown suppressed these effects.Transcriptomic analyses revealed that DLG3 activates signal transducer and activator of transcription 3(STAT3)signaling,a finding further corroborated by Western blot.Critically,treatment with the STAT3 inhibitor Stattic attenuated DLG3-driven proliferation and migration,supporting a DLG3-STAT3 oncogenic axis.Furthermore,in vivo studies validated the role of DLG3 in promoting tumor growth and its correlation with elevated STAT3 signaling,consistent with our in vitro findings.Our findings establish DLG3 as a novel driver of breast cancer progression that directly activates STAT3 signaling.DLG3 thus represents both a potential prognostic biomarker and a promising therapeutic target for aggressive breast cancer subtypes,including triple-negative breast cancer.展开更多
Objective Tumor-associated macrophages(TAMs)contribute to chemoresistance in triple-negative breast cancer(TNBC),yet strategies to reprogram TAMs while enhancing chemotherapy efficacy remain limited.This study investi...Objective Tumor-associated macrophages(TAMs)contribute to chemoresistance in triple-negative breast cancer(TNBC),yet strategies to reprogram TAMs while enhancing chemotherapy efficacy remain limited.This study investigated whether Viscum album L.var.coloratum agglutinin(VCA)could sensitize TNBC cells to doxorubicin(DOX)and modulate TAM-mediated chemoresistance in three-dimensional(3D)co-culture models.Methods MDA-MB-231 TNBC cells were co-cultured with RAW264.7 macrophages in collagen-embedded 3D spheroids.Spheroid viability was assessed using an ATP-based luminescent assay.Cytokine secretion and epithelial-mesenchymal transition(EMT)markers were measured using ELISA and Western blotting.Drug synergy was evaluated using combination index(CI)calculations.Results VCA-DOX combination demonstrated synergistic cytotoxicity exclusively in co-culture spheroids(CI=0.72),reducing viability to 25.9%(p<0.001),while showing no synergy in monoculture(CI=1.52).Combination treatment decreased VEGF secretion by 49%and IL-6 by 74%,while elevating TNF-α2.7-fold,suggesting macrophage reprogramming.VCA enhanced E-cadherin expression while suppressing mesenchymal markers in co-culture spheroids and reduced Matrigel invasion by 60%(p<0.001).Conclusion VCA-DOX combination demonstrates synergistic anticancer effects through TAM reprogramming and enhanced chemosensitization specifically in 3D co-culture models,warranting further investigation for overcoming macrophage-mediated chemoresistance in TNBC.展开更多
In recent years,multidisciplinary treatment strategies have profoundly improved drug responses and survival outcomes of breast cancer(BC)patients.However,there is an urgent need for novel therapies for BC patients who...In recent years,multidisciplinary treatment strategies have profoundly improved drug responses and survival outcomes of breast cancer(BC)patients.However,there is an urgent need for novel therapies for BC patients who are heavily treated or develop resistance to conventional treatment regimens.Radionuclide therapy(RT)and targeted radionuclide therapy(TRT)have emerged as paradigm-shifting therapeutic approaches for BC,which enable functions of both imaging and localised treatment.They utilise radionuclides that can selectively bind to biomarkers overexpressing on BC cells,allowing precise delivery and localised tumour irradiation.Moreover,several types of radionuclides possess‘cross-fire’effects that result in the eradication of neighbouring tumour cells lacking the biomarker expression.In the current review,we summarise the potential biomarkers for the development of RT and TRT that can be employed in the treatment of BC,including receptor markers of ER,PR and HER2,together with other markers of Trop2,PD-1,EGFR,GRPR and PSMA.展开更多
Traditional artificial intelligence(AI)-based methods for breast cancer diagnosis often rely on a single modality,such as ultrasound images.With the rise of multimodal approaches,multiple data sources,including imagin...Traditional artificial intelligence(AI)-based methods for breast cancer diagnosis often rely on a single modality,such as ultrasound images.With the rise of multimodal approaches,multiple data sources,including imaging from diverse medical modalities,structured clinical information,and unstructured medical reports,are increasingly integrated to provide richer and more informative signals for model training.This survey reviews the data modalities employed in AI-based breast cancer research,examines common multimodal combinations and fusion strategies,and discusses their applications across clinical tasks such as diagnosis,treatment planning,and outcome prediction.By consolidating current literature and identifying critical gaps,this survey aims to guide future research toward the development of reliable,clinically relevant multimodal AI systems for use in breast cancer management.展开更多
Triple-negative breast cancer(TNBC)presents significant diagnostic and therapeutic challenges due to the lack of targeted treatments,rapid progression,high recurrence and metastasis rates,and overall poorer prognosis....Triple-negative breast cancer(TNBC)presents significant diagnostic and therapeutic challenges due to the lack of targeted treatments,rapid progression,high recurrence and metastasis rates,and overall poorer prognosis.Herein,the targeted theranostic platform of cysteine-modified gold nanodots-sulfhydrated luteinizing hormone releasing hormone(CGN-SLR)nanosystem was designed for target recognition and precise dual-mode imaging-guided photothermal therapy(PTT)against TNBC.On the one hand,the CGN-SLR nanosystem can serve as an ideal targeting fluorescent probe and computed tomography(CT)enhancer to facilitate the accurate diagnosis and surgical guidance of TNBC.On the other hand,the CGN-SLR nanosystem with great targeting and PTT ability can significantly inhibit the growth of TNBC,without causing harm to normal tissues and healthy organs.It provides an effective strategy for the diagnosis and treatment of TNBC through the rational design of multifunctional nanoplatform with target recognition,multiple imaging guidance/monitoring,and high-efficiency PTT.展开更多
Objectives:Vascular endothelial growth factor(VEGF)regulates tumor vascularization in response to hypoxia and inflammatory signals.The polyphenol curcumin is supposed to interfere with inflammation-induced VEGF secret...Objectives:Vascular endothelial growth factor(VEGF)regulates tumor vascularization in response to hypoxia and inflammatory signals.The polyphenol curcumin is supposed to interfere with inflammation-induced VEGF secretion and might therefore support anti-VEGF-based treatments.We aimed to investigate the interaction between curcumin and the inflammatory cytokine Interleukin-1β(IL-1β)for VEGF secretion in breast cancer cell lines representing major breast cancer subtypes.Methods:VEGF in cell cultures was detected by Western blot and enzyme-linked immunosorbent assay(ELISA).Kinase phosphorylation was investigated by Western blotting.Gene expressions were analyzed by correlation tests.VEGF was evaluated in a retrospective breast cancer cohort by immunohistochemistry.Survival analysis was performed by the Kaplan-Meier algorithm.Results:VEGF secretion and kinase signaling in response to IL-1βand curcumin varied significantly for the cell lines MCF-7(Luminal A),SK-BR-3(HER2/neu+),MDA-MB-231,and UACC-3199(triple negative breast cancer).All cell lines increased VEGF secretion under hypoxia,but IL-1βincreased VEGF secretion only in MCF-7 cells.Curcumin inhibited VEGF secretion in MDA-MB-231,but increased it in MCF-7 and UACC-3199 cells.Curcumin induced phosphorylation of extracellular signal-regulated kinase(ERK)and p38-mitogen-activated protein kinase(p38-MAPK).However,inhibitor experiments demonstrated that ERK was more important for VEGF secretion.In gene expression data from the METABRIC study,no clear correlation of hypoxia-induced factor(HIF1A),IL-1β,and VEGF mRNA expression was observed;however,a suggested crosstalk of hypoxia and inflammatory pathways was observed.Conclusion:These dissimilar responses of breast cancer cell lines suggest that therapy efficiency with anti-VEGF,anti-IL-1β,or curcumin will also vary within breast cancers.展开更多
基金supported by the Zhejiang Provincial Natural Science Foundation of China(grant no.LQ22H150005).
文摘Breast augmentation with implants is a popular cosmetic surgery that enhances breast volume and contour through various placement planes.In this review,we examine the impact of subglandular,subpectoral,and subfascial implant planes on postoperative outcomes and complication rates.Subglandular placement offers simplicity but is associated with higher risks of capsular contracture,hematoma,and rippling in patients with low tissue coverage.The subpectoral plane,widely adopted for its natural appearance and reduced capsular contracture risk,may cause dynamic deformity due to muscle contraction.Although technically challenging,the subfascial plane combines the benefits of soft tissue support and reduced implant displacement.We highlight the importance of choosing an optimal implant plane tailored to each patient’s anatomical and aesthetic needs to enhance surgical outcomes and minimize complications.Further research is needed to validate long-term efficacy,particularly for subfascial placement.
基金supported by the National Natural Science Foundation of China(Grant Nos.82230057 and 82272859)the National Key R&D Program of China(Grant No.2022YFC2505101).
文摘Introduction,Breast cancer is the most common cancer type in adolescents and young adults<40 years of age,accounting for 30%of cancers in this age group1.Breast cancer in the young presents significant challenges for patients and society,including more aggressive tumor biology,poor prognosis,genetic susceptibility,fertility preservation,and complex psychosocial issues.Moreover,because of the markedly younger median age of breast cancer,the proportion of young breast cancer patients in China is significantly higher than Western countries2.The first Young Breast Cancer in China(YBCC)consensus meeting was held in Guangzhou,China in December 2021 to address exclusive challenges and requirements facing young patients with breast cancer.Chinese medical experts from multiple specialties had an extensive discussion and formulated a consensus over several hot topics in young patients with breast cancer.The“Expert Consensus on the Diagnosis and Treatment of Young Breast Cancer in China(2022 edition)”published in the Chinese Medical Journal has garnered significant attention3,highlighting enormous interest in the YBCC consensus in the medical community and public.
基金National High Level Hospital Clinical Research Funding,Grant/Award Numbers:2025-PUMCH-A-147,2022-PUMCH-B-039Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(CIFM),Grant/Award Number:2021-I2M-1-014。
文摘Background:Sclerosing adenosis(SA)and breast cancer(BC)often exhibit overlapping clinical,imaging,and pathological characteristics,making them difficult to differentiate.SA may also coexist with BC(SA+BC),including ductal carcinoma in situ(SA-DCIS)and invasive breast cancer(SA-IBC),which complicates diagnosis even when core-needle biopsy(CNB)suggests SA.This study aimed to develop interpretable AI-based binary and ternary classification models that leverage clinical and imaging features to distinguish SA-only from SA+BC and to further differentiate among SA-only,SA-DCIS,and SA-IBC.Methods:We retrospectively analyzed a cohort of 726 patients with SA(January 2006 to December 2021),comprising 537 SA-only and 189 SA+BC cases(90 SA-DCIS,99 SA-IBC).Multiple machine learning algorithms-logistic regression,support vector machine,decision tree,XGBoost,and random forest-were compared using AUC,accuracy,F1-score,and C-index.Model interpretability was assessed with SHAP to elucidate feature contributions and identify key predictors.Additionally,we incorporated an independent external validation cohort consisting of 113 patients to verify the model's effectiveness.
基金supported by Rural Health Research Institute,Charles Sturt University.
文摘Breast cancer(BC)remains the most frequently diagnosed malignancy worldwide,with an estimated 2.3 million new cases and approximately 685,000 deaths reported in 2020.Forecasts suggest a substantial rise in global incidence,with new annual cases projected to reach 3.2 million by 2050,representing a 39%increase.Additionally,BC is expected to account for approximately 7.7%of the anticipated$25.2 trillion global economic burden associated with cancer by 2050.These trends underscore an urgent need for affordable,widely accessible and effective therapeutic strategies,particularly in low-and middle-income countries.Statins,commonly prescribed for the treatment of hypercholesterolaemia via inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A(HMG-CoA)reductase,have garnered increasing interest for their potential anticancer properties.This review focuses on the mechanistic underpinnings and therapeutic implications of statin use,particularly simvastatin,in the context of BC.Statins exert their primary effect through inhibition of the mevalonate pathway,which is crucial for cholesterol and isoprenoid biosynthesis.Disruption of this pathway impairs the prenylation of key signalling proteins,including members of the Ras and Rho GTPase families,which are essential for cancer cell proliferation,survival and metastasis.Preclinical evidence has demonstrated that simvastatin can induce tumour cell apoptosis,arrest cell-cycle progression and inhibit oncogenic signalling pathways.These effects have been particularly pronounced in hormone receptor-negative and triple-negative breast cancer(TNBC)subtypes,which are often associated with poor prognosis and limited treatment options.Epidemiological and observational studies further support a potential association between statin use and reduced BC recurrence and mortality.Nevertheless,robust evidence from randomised controlled trials remains limited,and further investigation is required to establish causality and define optimal therapeutic regimens.Given their well-established safety profile,global accessibility and pleiotropic effects,statins,especially simvastatin,represent a promising class of repurposed drugs in the adjuvant treatment of BC.This review synthesises evidence from the past two decades,highlighting the need for continued clinical research to validate and optimise the use of statins as adjunctive agents in BC therapy.
文摘Breast cancer remains a global health challenge with greater than 2.3 million new cases diagnosed annually 1,according to the World Health Organization1.Management of breast cancer is shaped by a complex interplay of international guidelines,regional adaptations,and the rapidly evolving fields of precision medicine and artificial intelligence(AI).
基金supported by the National Natural Science Foundation of China(Grant No.82404074)the Science and Technology Major Project(Grant No.2024ZD0519805).
文摘Breast cancer is the most common malignant tumor among women globally and poses a major public health challenge due to limitations in traditional diagnostic and treatment processes,such as subjective interpretation biases and inefficient multidimensional data integration.Artificial intelligence(AI),particularly deep learning and machine learning technologies,has emerged as a transformative tool in addressing these issues.Clinically,AI has been widely applied in imaging screening to improve detection rates and reduce reading time,digital pathology for precise tumor typing and gene mutation prediction,treatment decisionsupport systems to enhance guideline compliance,and drug research and development to accelerate target identification and virtual screening.Despite these achievements,AI implementation faces challenges,such as data standardization issues,limited model generalization,low clinical accessibility,and unclear ethical-legal responsibilities,which require targeted solutions that include national data standards,multi-center training,hierarchical physician training,and explainable AI.Future directions involve multimodal data integration,human-AI collaborative multidisciplinary team models,and extension to full-cycle health management from prevention-to-rehabilitation.This review provides a systematic overview of the role of AI in breast cancer care,offering insights for clinical practice and scientific research innovation,and supporting the transition toward personalized and intelligent medicine in oncology.
基金supported by the Regional Innovation System&Education(RISE)program through the(Chungbuk Regional Innovation System&Education Center),funded by the Ministry of Education(MOE)and the(Chungcheongbuk-do),Republic of Korea(2025-RISE-11-014-03)In addition,this work was also supported by the Sejong Fellowship through the NRF funded by the Ministry of Science and ICT(RS-2025-00557567)to HKL.
文摘Objectives:Progesterone(P4)is believed to inhibit breast cancer growth,but its role in counteracting estrogen(E2)-driven progression remains unclear.This study aimed to investigate the inhibitory effect of P4 on E2-induced cell proliferation,migration,and invasion in Estrogen receptor(ER)+/progesterone receptor(PR)+breast cancer cells by examining its regulatory role in the epithelial-mesenchymal transition(EMT).Methods:ER and PRpositive MCF-7 clonal variant(MCF-7 CV)breast cancer cells were treated with E2 and co-treated with various concentrations of P4.The effects on cell proliferation,migration,and invasion were assessed.The expression of key EMT markers(E-cadherin,N-cadherin,vimentin),transcription factors(Snail,Slug),and apoptosis-related genes(p53,B-cell lymphoma 2[BCL-2],BCL2-associated X[BAX])were analyzed.Results:P4 significantly inhibited E2-induced cell proliferation in a dose-dependent manner.In the presence of E2,P4 treatment reversed EMT characteristics by increasing E-cadherin while decreasing N-cadherin,vimentin,Snail,and Slug.Consequently,P4 inhibited E2-stimulated cell migration and invasion.Furthermore,P4 treatment promoted apoptosis by upregulating BAX and p53 and downregulating BCL-2.Conclusion:Progesterone can counteract estrogen-driven breast cancer progression in ER+/PR+cells by inhibiting proliferation,reversing the EMT process,and inducing apoptosis.These findings provide mechanistic insight into the protective role of PR signaling in breast cancer.
基金supported by the Institute of Information&Communications Technoljogy Planning&Evaluation(IITP)-Innovative Human Resource Development for Local Intellectualization Program grant funded by the Korea government(MSIT)(IITP-2026-RS-2022-00156334,50%)the National Research Foundation of Korea(NRF)grant funded by the Korea government(MSIT)(No.2021R1C1C2011105,50%).
文摘Sign language is a primary mode of communication for individuals with hearing impairments,conveying meaning through hand shapes and hand movements.Contrary to spoken or written languages,sign language relies on the recognition and interpretation of hand gestures captured in video data.However,sign language datasets remain relatively limited compared to those of other languages,which hinders the training and performance of deep learning models.Additionally,the distinct word order of sign language,unlike that of spoken language,requires context-aware and natural sentence generation.To address these challenges,this study applies data augmentation techniques to build a Korean Sign Language dataset and train recognition models.Recognized words are then reconstructed into complete sentences.The sign recognition process uses OpenCV and MediaPipe to extract hand landmarks from sign language videos and analyzes hand position,orientation,and motion.The extracted features are converted into time-series data and fed into a Long Short-Term Memory(LSTM)model.The proposed recognition framework achieved an accuracy of up to 81.25%,while the sentence generation achieved an accuracy of up to 95%.The proposed approach is expected to be applicable not only to Korean Sign Language but also to other low-resource sign languages for recognition and translation tasks.
基金supported by National Research Foundation(NRF)of Korea grants funded by the Korean government,the Ministry of Science and ICT[NRF-2022R1A2C1006737 to Joo-Won Park,NRF-2022R1I1A1A0106408112 to Min Hee Kim].
文摘Breast cancer is one of the most prevalent malignancies among women and comprises a heterogeneous spectrum of molecular subtypes with distinct biological behaviors.Among various regulatory molecules,sphingolipids play pivotal roles in dynamically modulating fundamental cellular processes such as proliferation,apoptosis,and metastasis through metabolic interconversions,including phosphorylation,glycosylation,and the generation of sphingosine-1-phosphate.This review aims to elucidate the mechanisms through which sphingolipid metabolism orchestrates cancer cell fate and drives breast cancer progression.Particular emphasis is placed on the balance between proapoptotic ceramides and pro-survival metabolites,such as sphingosine-1-phosphate,which collectively influence tumor growth and the therapeutic response.Additional sphingolipid species,including glucosylceramide and gangliosides(GD2,GD3,GM1,and GM3),have also been implicated in promoting breast cancer development.Furthermore,sphingolipid-based therapeutic strategies,including immunotherapy and antibody therapy,are discussed.By providing a comprehensive overview of sphingolipid metabolism,this review aims to identify novel therapeutic targets that may help overcome treatment resistance and improve clinical outcomes in breast cancer.
基金supported by the Non-communicable Chronic Diseases National Science and Technology Major Project(Grant No.2025ZD0544003).
文摘The landscape of breast cancer treatment has undergone a transformative shift with the integration of immunotherapy.Historically considered a“cold”tumor with limited immunogenicity,breast cancer management was dominated by surgery,chemotherapy,radiotherapy,and targeted therapies1.However,the advent of immune checkpoint inhibitors(ICIs)has challenged this paradigm,opening a new frontier.The initial breakthrough in triple-negative breast cancer(TNBC)demonstrated that a subset of patients could derive profound and durable clinical benefit from pembrolizumab and atezolizumab2,3.Today,precision immunotherapy aims to identify the patients most likely to respond,to convert immunologically silent tumors into responsive tumors,and to strategically combine immunotherapies with other modalities to overcome resistance.This evolution from empirical application to biomarker-driven strategies marks the critical juncture at which we stand,transitioning promising clinical trial data into refined,effective,and accessible clinical practice4.Recent key clinical studies on breast cancer immunotherapy are summarized in Table 1.
基金supported by the Institute of Information&Communications Technology Planning&Evaluation(IITP)grant funded by the Korea government(MSIT)[RS-2021-II211341,Artificial Intelligence Graduate School Program(Chung-Ang University)],and by the Chung-Ang University Graduate Research Scholarship in 2024.
文摘Legal case classification involves the categorization of legal documents into predefined categories,which facilitates legal information retrieval and case management.However,real-world legal datasets often suffer from class imbalances due to the uneven distribution of case types across legal domains.This leads to biased model performance,in the form of high accuracy for overrepresented categories and underperformance for minority classes.To address this issue,in this study,we propose a data augmentation method that masks unimportant terms within a document selectively while preserving key terms fromthe perspective of the legal domain.This approach enhances data diversity and improves the generalization capability of conventional models.Our experiments demonstrate consistent improvements achieved by the proposed augmentation strategy in terms of accuracy and F1 score across all models,validating the effectiveness of the proposed method in legal case classification.
基金supported by the National Natural Science Foundation of China(Grant No.:82560497,82260502,82272656)Guizhou Provincial Basic Research Program(Grant No.:Natural Science,MS[2025]-495)Talent Fund of Guizhou Provincial People’s Hospital(Grant No.:2022-33).
文摘Background:As a heterogeneous disease,breast cancer requires refined classification frameworks that can effectively guide targeted therapies.However,traditional methods fail to capture the comprehensive molecular insights needed for this purpose.Methods:To comprehensively capture breast cancer heterogeneity,we employed integrative clustering that incorporates six molecular features from 670 breast cancer samples.Ten distinct clustering algorithms were combined to ensure robust subtype identification,and the identified subtypes were validated in four independent datasets.Subsequently,we constructed a survival support vector machine prognostic model based on key molecular features to enhance survival prediction and clinical applicability.Results:Five novel subtypes were identified:consensus subtypes 1–5(CS1–CS5).CS2 was an aggressive subtype with elevated TP53 mutation rates,high tumor mutational burden,and strong sensitivity to YM-155 and ispinesib.Conversely,CS5 exhibited stable genomics with enhanced nucleotide excision repair and favorable prognoses.CS2 and CS4 showed enriched immune checkpoint expression,indicating potential immunotherapy responsiveness,while CS1 and CS5 exhibited immune-cold profiles.The survival support vector machine model effectively predicted survival outcomes across independent datasets.Conclusions:The refined breast cancer classification framework developed in this research uncovers new insights into molecular heterogeneity,enhances risk stratification,and enables the identification of promising therapeutic targets.The potential of this framework to optimize personalized treatment strategies warrants further clinical validation.
基金funded by Al Jalila Foundation-Research Grant(AJF2023-078)to SSMS.
文摘Objectives:Breast cancer(BC)is the leading cause of cancer-related mortality in women,largely due to metastasis.This study aims to explore the role of purine nucleoside phosphorylase(PNP),a key enzyme in purine metabolism,in the aggressiveness and metastatic behavior of BC.Methods:A comprehensive analysis was performed using in silico transcriptomic data(n=2509 patients),immunohistochemical profiling of BC tissues(n=103),and validation through western blotting in multiple BC cell lines.Gene expression and survival analyses were conducted using Tumor Immune Estimation Resource(TIMER),Gene Expression Profiling Interactive Analysis 2(GEPIA2),and the cBioPortal for cancer genomics(cBioPortal)platforms.Correlations between PNP and key epithelial–mesenchymal transition(EMT)markers,molecular subtypes,tumor grades,and stages were examined.Results:PNP was significantly overexpressed in human epidermal growth factor receptor 2(HER-2)-positive and triple-negative BCs compared to luminal subtypes.High PNP levels were strongly associated with advanced BC stages,high-grade tumors,EMT phenotypes,and poor overall survival.Notably,HER-2 inhibition suppressed PNP expression,while PNP gene silencing induced HER-2 upregulation,revealing a reciprocal regulatory loop.Dual inhibition of PNP and HER-2 resulted in a significant reduction in cell viability compared to HER-2 inhibition alone.Conclusion:Collectively,PNP emerges as a promising biomarker of BC aggressiveness and progression.Its reciprocal interaction with HER-2 underscores its potential as a therapeutic target.Dual targeting of PNP and HER-2 may offer a novel strategy for improving outcomes in aggressive BC subtypes.
基金supported by grants from the National Natural Science Foundation of China(Grant Nos.82573747,82172873,W2421095,and 82503888)National Science and Technology Major Project(Grant No.2025ZD0543900)+2 种基金Natural Science Foundation of Shandong Province(Grant Nos.ZR2024LMB011 and ZR2024QH058)Taishan Scholars Program of Shandong Province(Grant No.tsqn202211337)Collaborative Academic Innovation Project of Shandong Cancer Hospital(Grant No.GF003).
文摘Neoadjuvant therapy(NAT)has become the standard treatment for patients with locally advanced breast cancer and stage II-III HER2-positive(HER2+)or triple-negative breast cancer(TNBC)1,2.It is essential to accurately mark the primary breast tumor and positive axillary lymph nodes(ALNs)prior to NAT to ensure precise surgical excision,guide axillary downstaging,and guarantee reliable lesion retrieval for pathologic evaluation3.The false-negative rate of sentinel lymph node biopsy(SLNB)after NAT can be reduced to<10%by applying modalities,such as the identification of≥3 sentinel lymph nodes(SLNs)with dual-mapping techniques or removal of the marked lymph node with target axillary dissection(TAD)according to the ASCO,NCCN,and CBCS guidelines3-5.However,there is a lack of consensus regarding the optimal methods and materials for accurate marking6,7.Conventional techniques include clip placement,guidewire localization,and carbon or ink tattooing,whereas wireless technologies,such as MagseedR,radiofrequency identification tags,SAVI SCOUTR,and radioactive iodine-125(125I)seeds,have also been adopted.Traditional marking techniques have a localization failure rate of approximately 10%.In contrast,the use of 125I seeds(with a radiation dose of 0.1-0.3 mCi)has significantly improved localization accuracy8,9.Nevertheless,owing to radioactive properties,concerns have been raised regarding the potential impact of 125I seed marking on assessing the pathologic complete response(pCR)after NAT10.Moreover,whether the influence of 125I seed marking on pCR could lead to suboptimal adjuvant treatment decisions and potentially compromise long-term oncologic outcomes has not been established.To investigate the potential impact of 125I seed placement on the pCR rate and long-term outcomes in breast cancer patients receiving NAT,we conducted a retrospective cohort study utilizing propensity score matching(PSM).
文摘Breast cancer(BRCA)is characterized by high heterogeneity,with aggressive subtypes frequently showing poor prognosis and resistance to conventional therapies,making the discovery of new therapeutic targets and strategies imperative.Although elevated expression of discs large homolog 3(DLG3)has been reported in BRCA,its functional role in disease progression remains unclear.We performed bioinformatic analyses of clinical datasets to evaluate the prognostic significance of DLG3 expression in BRCA patients.In vitro gain-and loss-of-function experiments were conducted to assess the impact of DLG3 on BRCA cell proliferation,migration,and colony formation.Transcriptomic profiling,coupled with pharmacological inhibition,was employed to identify and validate downstream signaling pathways.Additionally,we extended our validation to an in vivo model to assess the role of DLG3 in tumor progression.We found that elevated DLG3 levels correlated with poor prognosis in breast cancer patients.Functionally,DLG3 overexpression significantly promoted cell proliferation and migration in estrogen receptor-positive MCF7 and triple-negative MDA-MB-231 breast cancer cells,whereas its knockdown suppressed these effects.Transcriptomic analyses revealed that DLG3 activates signal transducer and activator of transcription 3(STAT3)signaling,a finding further corroborated by Western blot.Critically,treatment with the STAT3 inhibitor Stattic attenuated DLG3-driven proliferation and migration,supporting a DLG3-STAT3 oncogenic axis.Furthermore,in vivo studies validated the role of DLG3 in promoting tumor growth and its correlation with elevated STAT3 signaling,consistent with our in vitro findings.Our findings establish DLG3 as a novel driver of breast cancer progression that directly activates STAT3 signaling.DLG3 thus represents both a potential prognostic biomarker and a promising therapeutic target for aggressive breast cancer subtypes,including triple-negative breast cancer.
基金supported by the Regional Innovation System&Education(RISE)program through the Jeollanamdo RISE center,funded by the Ministry of Education(MOE)and the Jeollanamdo,Republic of Korea(2025-RISE-14-003).
文摘Objective Tumor-associated macrophages(TAMs)contribute to chemoresistance in triple-negative breast cancer(TNBC),yet strategies to reprogram TAMs while enhancing chemotherapy efficacy remain limited.This study investigated whether Viscum album L.var.coloratum agglutinin(VCA)could sensitize TNBC cells to doxorubicin(DOX)and modulate TAM-mediated chemoresistance in three-dimensional(3D)co-culture models.Methods MDA-MB-231 TNBC cells were co-cultured with RAW264.7 macrophages in collagen-embedded 3D spheroids.Spheroid viability was assessed using an ATP-based luminescent assay.Cytokine secretion and epithelial-mesenchymal transition(EMT)markers were measured using ELISA and Western blotting.Drug synergy was evaluated using combination index(CI)calculations.Results VCA-DOX combination demonstrated synergistic cytotoxicity exclusively in co-culture spheroids(CI=0.72),reducing viability to 25.9%(p<0.001),while showing no synergy in monoculture(CI=1.52).Combination treatment decreased VEGF secretion by 49%and IL-6 by 74%,while elevating TNF-α2.7-fold,suggesting macrophage reprogramming.VCA enhanced E-cadherin expression while suppressing mesenchymal markers in co-culture spheroids and reduced Matrigel invasion by 60%(p<0.001).Conclusion VCA-DOX combination demonstrates synergistic anticancer effects through TAM reprogramming and enhanced chemosensitization specifically in 3D co-culture models,warranting further investigation for overcoming macrophage-mediated chemoresistance in TNBC.
基金Noncommunicable Chronic Diseases-National Science and Technology Major Project,Grant/Award Number:2023ZD0502200National Natural Science Foundation of China,Grant/Award Number:82103010+2 种基金Cultivation Project of Medical Oncology Key Foundation of Cancer HospitalChinese Academy of Medical Sciences,Grant/Award Number:CICAMS-MOCP2022004Joint Innovative Fund of Beijing Natural Science Foundation and Changping District,Grant/Award Number:L234004。
文摘In recent years,multidisciplinary treatment strategies have profoundly improved drug responses and survival outcomes of breast cancer(BC)patients.However,there is an urgent need for novel therapies for BC patients who are heavily treated or develop resistance to conventional treatment regimens.Radionuclide therapy(RT)and targeted radionuclide therapy(TRT)have emerged as paradigm-shifting therapeutic approaches for BC,which enable functions of both imaging and localised treatment.They utilise radionuclides that can selectively bind to biomarkers overexpressing on BC cells,allowing precise delivery and localised tumour irradiation.Moreover,several types of radionuclides possess‘cross-fire’effects that result in the eradication of neighbouring tumour cells lacking the biomarker expression.In the current review,we summarise the potential biomarkers for the development of RT and TRT that can be employed in the treatment of BC,including receptor markers of ER,PR and HER2,together with other markers of Trop2,PD-1,EGFR,GRPR and PSMA.
文摘Traditional artificial intelligence(AI)-based methods for breast cancer diagnosis often rely on a single modality,such as ultrasound images.With the rise of multimodal approaches,multiple data sources,including imaging from diverse medical modalities,structured clinical information,and unstructured medical reports,are increasingly integrated to provide richer and more informative signals for model training.This survey reviews the data modalities employed in AI-based breast cancer research,examines common multimodal combinations and fusion strategies,and discusses their applications across clinical tasks such as diagnosis,treatment planning,and outcome prediction.By consolidating current literature and identifying critical gaps,this survey aims to guide future research toward the development of reliable,clinically relevant multimodal AI systems for use in breast cancer management.
基金supported by the Natural Science Foundation of Jilin Province(No.SKL202302002).
文摘Triple-negative breast cancer(TNBC)presents significant diagnostic and therapeutic challenges due to the lack of targeted treatments,rapid progression,high recurrence and metastasis rates,and overall poorer prognosis.Herein,the targeted theranostic platform of cysteine-modified gold nanodots-sulfhydrated luteinizing hormone releasing hormone(CGN-SLR)nanosystem was designed for target recognition and precise dual-mode imaging-guided photothermal therapy(PTT)against TNBC.On the one hand,the CGN-SLR nanosystem can serve as an ideal targeting fluorescent probe and computed tomography(CT)enhancer to facilitate the accurate diagnosis and surgical guidance of TNBC.On the other hand,the CGN-SLR nanosystem with great targeting and PTT ability can significantly inhibit the growth of TNBC,without causing harm to normal tissues and healthy organs.It provides an effective strategy for the diagnosis and treatment of TNBC through the rational design of multifunctional nanoplatform with target recognition,multiple imaging guidance/monitoring,and high-efficiency PTT.
基金funded by the Deutsche Forschungsgemeinschaft(DFG)grant number(KA2663/3-1)supported by the Ministry of Science,Research and Cultural Affairs of the State of Brandenburg.
文摘Objectives:Vascular endothelial growth factor(VEGF)regulates tumor vascularization in response to hypoxia and inflammatory signals.The polyphenol curcumin is supposed to interfere with inflammation-induced VEGF secretion and might therefore support anti-VEGF-based treatments.We aimed to investigate the interaction between curcumin and the inflammatory cytokine Interleukin-1β(IL-1β)for VEGF secretion in breast cancer cell lines representing major breast cancer subtypes.Methods:VEGF in cell cultures was detected by Western blot and enzyme-linked immunosorbent assay(ELISA).Kinase phosphorylation was investigated by Western blotting.Gene expressions were analyzed by correlation tests.VEGF was evaluated in a retrospective breast cancer cohort by immunohistochemistry.Survival analysis was performed by the Kaplan-Meier algorithm.Results:VEGF secretion and kinase signaling in response to IL-1βand curcumin varied significantly for the cell lines MCF-7(Luminal A),SK-BR-3(HER2/neu+),MDA-MB-231,and UACC-3199(triple negative breast cancer).All cell lines increased VEGF secretion under hypoxia,but IL-1βincreased VEGF secretion only in MCF-7 cells.Curcumin inhibited VEGF secretion in MDA-MB-231,but increased it in MCF-7 and UACC-3199 cells.Curcumin induced phosphorylation of extracellular signal-regulated kinase(ERK)and p38-mitogen-activated protein kinase(p38-MAPK).However,inhibitor experiments demonstrated that ERK was more important for VEGF secretion.In gene expression data from the METABRIC study,no clear correlation of hypoxia-induced factor(HIF1A),IL-1β,and VEGF mRNA expression was observed;however,a suggested crosstalk of hypoxia and inflammatory pathways was observed.Conclusion:These dissimilar responses of breast cancer cell lines suggest that therapy efficiency with anti-VEGF,anti-IL-1β,or curcumin will also vary within breast cancers.
